Search Technologies
Displaying 1 - 10 of 26 results
Researchers at the University of Maryland have created hundreds of innovations that are available for licensing. Our Discovery Portfolio contains an exciting mix of vaccines, drug targets, therapeutics, devices and cutting edge techniques that promise to make a quantifiable impact on human health and the environment.
Search by keyword:
-
Functional Myelination of Neurons
Published Tuesday, May 7, 2024Summary This invention is a significant advancement in regenerative medicine, offering a novel stem cell-based therapy for demyelinating diseases. It utilizes melanocyte stem cells (MeSCs) from the skin to differentiate into cells capable of myelination, addressing diseases like...
Investigator(s): Thomas Hornyak and Sandeep Joshi
Categories: Therapeutics, Biologics, Stem Cells, Methods of Treatment
Docket: TH-2015-020
-
Compositions and Methods for Delivering Nucleic Acids to Cells
Published Wednesday, December 6, 2023Summary This invention provides a breakthrough in gene therapy and molecular biology, featuring a non-viral vector system for delivering nucleic acids to cells. It utilizes a polyplex particle with acetylated polyethylenimine (Ac-PEI) and an anionic biomaterial envelope, reducing...
Investigator(s): Ryan Pearson and Atanu Chakraborty
Categories: Therapeutics, Biologics, Methods of Treatment
Docket: RP-2020-012
-
Water Proton NMR for Monitoring Sedimentation Process of Multiphase Mixtures
Published Tuesday, June 27, 2023Summary The technology developed by the University of Maryland, Baltimore utilizes water proton Nuclear Magnetic Resonance (NMR) to monitor the sedimentation process in multiphase mixtures in real-time. This analytical method...
Investigator(s): Bruce Yu, Marc Taraban
Categories: Research Tools, Antibodies, & Reagents, Therapeutics, Small molecules, Chemicals, Biologics, Vaccines
Keyword(s): Sedimentation Monitoring, Multiphase Mixtures, Water Proton NMR, Pharmaceutical, Specialty Chemical, Specialty Materials
Docket: BY-2020-149
-
Real Time in-situ Monitoring of Drug Product Degradation Using Water Proton NMR
Published Wednesday, May 17, 2023Summary This technology uses NMR spectroscopy to measure changes in the NMR signal of water, which is sensitive to changes in the chemical environment of the drug molecules it interacts with. This patented method allows for...
Investigator(s): Bruce Yu, Marc Taraban, Katharine Briggs
Categories: Devices, Diagnostics, Therapeutics, Small molecules, Biologics, Vaccines, Vaccine, Other
Keyword(s): NMR, Quality Control, vaccine, Drug Manufacturing, Freeze-Thaw
Docket: BY-2020-079
-
Noninvasive Quantitation of Full Versus Empty Capsids Using Water Proton NMR
Published Wednesday, May 17, 2023Summary This invention proposes a method for using NMR relaxation rates to determine whether capsid preparations contain empty or full viral capsids and to quantify the capsid content of the preparation....
Investigator(s): Bruce Yu, Marc Taraban
Categories: Devices, Diagnostics, Therapeutics, Small molecules, Biologics, Vaccines, Vaccine, Other
Keyword(s): NMR, Quality Control, vaccine, Drug Manufacturing, Freeze Thaw
Docket: BY-2020-059
-
Detection of Pharmaceutical Product Freezing History using Water Proton NMR
Published Wednesday, May 17, 2023Summary Researchers at UMB have created an innovative method that employs water proton nuclear magnetic resonance (NMR) spectroscopy to detect the freezing history of pharmaceutical products. This technology compares the...
Investigator(s): Bruce Yu, Marc Traban, Katharine Briggs
Categories: Devices, Therapeutics, Biologics, Vaccines, Vaccine, Other
Keyword(s): NMR, Quality Control, vaccine, Drug Manufacturing, Freeze-Thaw
Docket: BY-2019-081
-
Inhibition of L-Plastin Activity in Osteoclasts to Reduce Bone Loss
Published Monday, March 11, 2019Osteoclasts (OCs) are specialized cell types that develop a focused microenvironment where bone matrix degradation can occur for the process of bone resorption or bone breakdown. Bone breakdown by osteoclasts requires the formation of tight sealing zone or ring in order for efficient focal bone breakdown to occur. L-plastin (LPL) is a...
Investigator(s): Meenakshi Chellaiah
Categories: Therapeutics, Biologics
Keyword(s): osteoporosis bone loss peptide
Docket: MC-2015-066
-
Monoclonal antibodies inhibiting fibrin-VLDL receptor-dependent inflammation
Published Tuesday, January 22, 2019Fibrin is a fibrous, non-globular protein involved in blood clotting and promotes leukocyte transmigration through its interaction with the endothelial cell receptor, the very low density lipoprotein (VLDL) receptor. The VLDL receptor is predominantly expressed in the heart, skeletal muscle, fat, brain and macrophages and involved in neural...
Investigator(s): Leonid Medved, Sergiy Yakovlev, Dudley Strickland
Categories: Therapeutics, Biologics
Keyword(s): Cardiology, antibody, inflammation, fibrin
Docket: LM-2016-049
-
Hyper-glycosylated Antibodies with Selective Fc Receptor Binding
Published Friday, February 16, 2018This technology is a set of hyper-glycosylated antibodies that have been modified in the Fc domain of the antibody to either enhance or reduce the affinity of the Fc region to the Fc γ...
Investigator(s): Eric Sundberg, Beatriz Trastoy-Bello
Categories: Therapeutics, Biologics
Keyword(s): Immunology
Docket: ES-2013-128
-
Giant obscurins and their uses in cancer prognosis and therapy
Published Wednesday, February 7, 2018Approximately 20% of cancer patients diagnosed annually in the US have metastatic cancer, which is associated with much poorer prognoses compared to patients with localized disease. Accurately determining which patients are at risk of developing metastases is a major clinical challenge. Giant obscurins, encoded by the single obscn gene, are...
Investigator(s): Aikaterini Kontrogianni-Konstantopoulos, Konstantinos Konstantopoulos, Marey Shriver, Nicole Perry
Categories: Biomarker, Therapeutics, Biologics
Keyword(s): oncology, antibody
Docket: AK-2013-059